Enpatoran Phase 2 Trial Reports Symptom Improvement in Cutaneous Lupus
An oral TLR7/8 inhibitor met its Phase 2 primary endpoint in cutaneous lupus erythematosus, per a Dermatology Advisor report, though full efficacy data remain unpublished.
Topic
Tlr Inhibitor
Topic